Somatotropic Peptides.
GHRH agonists and GH secretagogues for pituitary pulsatility research.
Somatotropic peptides allow investigation into the physiological pulsatile release of human growth hormone (hGH) and IGF-1. Combining GHRH analogs such as CJC-1295 with selective ghrelin receptor (GHSR) agonists like Ipamorelin stimulates pituitary somatotrophs without disrupting cortisol or prolactin baselines.
AVAILABLE RESEARCH COMPOUNDS
cjc-1295 + ipamorelin
sustainably stimulates growth hormone release in a pulsatile and selective manner, resulting in lean muscle mass improvement, enhanced fat loss, and increased vitality without altering biological stress.
tesamorelin
stimulates growth hormone secretion while reducing enzymatic susceptibility, resulting in a drastic and selective reduction of visceral and abdominal fat.
PRECLINICAL PHARMACOLOGICAL ANALYSIS
GHRH / GHSR Synergy and Pulsatility Preservation
Unlike exogenous hormone administration, secretagogues preserve endogenous somatostatin negative feedback loops. Tesamorelin, a stabilized GHRH analog with trans-3-hexenoic acid, binds somatotroph receptors to stimulate native secretion cascades.
FREQUENTLY ASKED QUESTIONS
Why are CJC-1295 and Ipamorelin frequently researched together?
They target distinct complementary receptors: CJC-1295 engages the GHRH receptor, while Ipamorelin activates the ghrelin receptor (GHSR-1a), yielding a synergistic secretory response.